Frequency Therapeutics Net Income
| KRRO Stock | 12.29 0.15 1.24% |
As of the 11th of February 2026, Frequency Therapeutics shows the Variance of 122.68, standard deviation of 11.08, and Mean Deviation of 4.97. Frequency Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Frequency Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 9.0622 | Revenue | Earnings Share (9.42) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -75.2 M | -71.5 M | |
| Net Loss | -75.2 M | -79 M | |
| Net Loss | (10.77) | (11.31) | |
| Net Income Per E B T | 0.90 | 0.80 |
Frequency | Net Income | Build AI portfolio with Frequency Stock |
Evaluating Frequency Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Frequency Therapeutics's fundamental strength.
Latest Frequency Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Frequency Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Frequency Therapeutics financial statement analysis. It represents the amount of money remaining after all of Frequency Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Frequency Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Frequency Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (83.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Frequency Net Income Regression Statistics
| Arithmetic Mean | (40,470,526) | |
| Coefficient Of Variation | (70.07) | |
| Mean Deviation | 25,747,622 | |
| Median | (20,237,000) | |
| Standard Deviation | 28,356,371 | |
| Sample Variance | 804.1T | |
| Range | 65.9M | |
| R-Value | (0.83) | |
| Mean Square Error | 270.8T | |
| R-Squared | 0.68 | |
| Significance | 0.000042 | |
| Slope | (4,645,100) | |
| Total Sum of Squares | 12865.3T |
Frequency Net Income History
Other Fundumenentals of Frequency Therapeutics
Frequency Therapeutics Net Income component correlations
Frequency Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Frequency Therapeutics is extremely important. It helps to project a fair market value of Frequency Stock properly, considering its historical fundamentals such as Net Income. Since Frequency Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Frequency Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Frequency Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Frequency diversify its offerings? Factors like these will boost the valuation of Frequency Therapeutics. Expected growth trajectory for Frequency significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Frequency Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Frequency Therapeutics requires distinguishing between market price and book value, where the latter reflects Frequency's accounting equity. The concept of intrinsic value - what Frequency Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Frequency Therapeutics' price substantially above or below its fundamental value.
Understanding that Frequency Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Frequency Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Frequency Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Frequency Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Frequency Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Frequency Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Frequency Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Frequency Therapeutics or generate 0.0% return on investment in Frequency Therapeutics over 90 days. Frequency Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Frequency Therapeutics is entity of United States More
Frequency Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Frequency Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Frequency Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 83.21 | |||
| Value At Risk | (6.05) | |||
| Potential Upside | 10.98 |
Frequency Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Frequency Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Frequency Therapeutics' standard deviation. In reality, there are many statistical measures that can use Frequency Therapeutics historical prices to predict the future Frequency Therapeutics' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.03) |
Frequency Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 4.97 | |||
| Coefficient Of Variation | (6,569) | |||
| Standard Deviation | 11.08 | |||
| Variance | 122.68 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 83.21 | |||
| Value At Risk | (6.05) | |||
| Potential Upside | 10.98 | |||
| Skewness | (5.64) | |||
| Kurtosis | 41.04 |
Frequency Therapeutics Backtested Returns
Frequency Therapeutics is somewhat reliable given 3 months investment horizon. Frequency Therapeutics secures Sharpe Ratio (or Efficiency) of 0.23, which denotes the company had a 0.23 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-two different technical indicators, which can help you to evaluate if expected returns of 1.16% are justified by taking the suggested risk. Use Frequency Therapeutics Mean Deviation of 4.97, standard deviation of 11.08, and Variance of 122.68 to evaluate company specific risk that cannot be diversified away. Frequency Therapeutics holds a performance score of 18 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 5.16, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Frequency Therapeutics will likely underperform. Use Frequency Therapeutics total risk alpha, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Frequency Therapeutics.
Auto-correlation | 0.87 |
Very good predictability
Frequency Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Frequency Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Frequency Therapeutics price movement. The serial correlation of 0.87 indicates that approximately 87.0% of current Frequency Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.87 | |
| Spearman Rank Test | 0.8 | |
| Residual Average | 0.0 | |
| Price Variance | 3.46 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Frequency Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Frequency Therapeutics reported net income of (83.58 Million). This is 124.49% lower than that of the Biotechnology sector and 219.32% lower than that of the Health Care industry. The net income for all United States stocks is 114.64% higher than that of the company.
Frequency Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Frequency Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Frequency Therapeutics could also be used in its relative valuation, which is a method of valuing Frequency Therapeutics by comparing valuation metrics of similar companies.Frequency Therapeutics is currently under evaluation in net income category among its peers.
Frequency Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Frequency Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Frequency Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Frequency Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (17.65) % | ||||
| Current Valuation | 66.8 M | ||||
| Shares Outstanding | 9.42 M | ||||
| Shares Owned By Insiders | 6.58 % | ||||
| Shares Owned By Institutions | 93.42 % | ||||
| Number Of Shares Shorted | 1.14 M | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 15.51 X | ||||
| Revenue | 2.27 M | ||||
| Gross Profit | 46 K | ||||
| EBITDA | (88.34 M) | ||||
| Net Income | (83.58 M) | ||||
| Total Debt | 44.77 M | ||||
| Book Value Per Share | 10.54 X | ||||
| Cash Flow From Operations | (60.07 M) | ||||
| Short Ratio | 3.91 X | ||||
| Earnings Per Share | (9.42) X | ||||
| Target Price | 19.33 | ||||
| Number Of Employees | 87 | ||||
| Beta | 2.44 | ||||
| Market Capitalization | 114.33 M | ||||
| Total Asset | 226.24 M | ||||
| Retained Earnings | (266.59 M) | ||||
| Working Capital | 116.57 M | ||||
| Net Asset | 226.24 M |
About Frequency Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Frequency Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Frequency Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Frequency Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Frequency Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Frequency Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Frequency Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Frequency Stock
The ability to find closely correlated positions to Frequency Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Frequency Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Frequency Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Frequency Therapeutics to buy it.
The correlation of Frequency Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Frequency Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Frequency Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Frequency Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Biotechnology sector continue expanding? Could Frequency diversify its offerings? Factors like these will boost the valuation of Frequency Therapeutics. Expected growth trajectory for Frequency significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Frequency Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Frequency Therapeutics requires distinguishing between market price and book value, where the latter reflects Frequency's accounting equity. The concept of intrinsic value - what Frequency Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Frequency Therapeutics' price substantially above or below its fundamental value.
Understanding that Frequency Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Frequency Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Frequency Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.